Press Room

13th American DDF Summit - Drug Delivery & Formulation

Start
Monday, September 18, 2023 - 00:00
End
Tuesday, September 19, 2023 - 00:00
Location: Boston, USA
Booth Number: Table #13
Hovione present at DDF Summit USA 2023 in Boston | Hovione

Hovione will be exhibiting at DDF - American Drug Delivery & Formulation Summit - from 18 to 19 September in Boston, USA. The 2023 Summit covers innovative solutions to the greatest challenges in pharmaceutical, biologics and device development.

Don’t miss the chance to speak with our experts – Table #13 – and learn more about Epidel™ an innovative technology with the ability to deliver sustained-release pharmaceuticals via surface erosion resulting in the ability to precisely tune pharmacokinetics to meet the target indication needs.
 

schedule a meeting

 

 

HOVIONE PRESENTATION

On Sep. 19th do not miss the Technology & Innovation” session: "Controlled and sustained drug delivery - How Epidel™ is changing long-acting drug development"

Márcio Temtem and Ian Parrag will present and share how this simplified pro-drug synthetic approach is being used to fine-tune the delivery of drugs with higher drug loads, precise dosing, and prolonged therapeutic effect.

Marcio Temtem | Hovione

Márcio Temtem
Senior Director, Strategic Business Management Products at Hovione

Chemical engineer with 15 years of experience in the Pharmaceutical Industry, in the fields of Solubility Enhancement, Dry Powder Inhalation, Controlled Release, and Drug Product Development. 

Twelve years of experience in R&D, from which the last 2 years were heading Hovione’s team in Portugal, Reporting to Hovione's Chief Technology Officer, with responsibilities over Process Chemistry Development, Drug Product Development, Analytical Development, Process Safety, Modelling, and PAT.

In the last 2.5 years, Senior Director and Strategic Business Management Products, Reporting to Hovione's CEO, with responsibilities for the P&L and Development of the Portfolio of Products at Hovione.

Ian Parrag - Ripple | Hovione

Ian Parrag
Vice President of R&D at Ripple Therapeutics

Ian is one of the founders of Ripple Therapeutics (RIPL) following its spin out from Interface Biologics (IBI) in 2020. Ian has a PhD in Chemical and Biomedical Engineering from the University of Toronto and a BASc in Biomedical Engineering (Engineering Science) from the University of Toronto.

Ian joined IBI in 2010 and is responsible for leading the R&D Team in the discovery of novel prodrugs for drug delivery and in managing the nonclinical development (Preclinical evaluation and Chemistry, Manufacturing, and Controls (CMC)) for controlled drug delivery product concepts through to clinical readiness. As lead inventor for the EpidelTM technology, Ian is also responsible for managing and strategically developing Ripple’s platform and patent portfolio. Ian has 7 granted US patents, 11 pending US patent applications, 3 pending PCT patent application and 24 pending international patent applications along with a robust pipeline of provisional patent applications in process. Ian is an author of 7 peer-reviewed journal articles and recipient of a Natural Sciences and Engineering Research Council of Canada Industrial R&D Fellowship.

 

Get to know more about Epidel™  

 

 

Let’s discuss your project together. Schedule a meeting with our experts.

Find more about the 13th American DDF Summit - Drug Delivery & Formulation.

 

Also in the Press Room

See All

Lisbon, Portugal – Hovione, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, Hovione joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At Hovione, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of Hovione. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” Hovione will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with Hovione’s sustainability ambitions.  Hovione remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024